Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia
The NOD-like receptor protein 3 (NLRP3) inflammasome plays a key role in lipid metabolism. We used an oral fat tolerance test (OFTT) to detect whether serum NLRP3 levels differed in people with different fat tolerances and evaluate whether NLRP3 was associated with impaired fat tolerance (IFT) and h...
Gespeichert in:
| Veröffentlicht in: | Endocrine Journal 2023, Vol.70(5), pp.529-539 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 539 |
|---|---|
| container_issue | 5 |
| container_start_page | 529 |
| container_title | Endocrine Journal |
| container_volume | 70 |
| creator | Zheng, Kunjie Li, Xiaolong Hou, Liping Gu, Wei Hou, Xiaoyu Wang, Chao Song, Guangyao |
| description | The NOD-like receptor protein 3 (NLRP3) inflammasome plays a key role in lipid metabolism. We used an oral fat tolerance test (OFTT) to detect whether serum NLRP3 levels differed in people with different fat tolerances and evaluate whether NLRP3 was associated with impaired fat tolerance (IFT) and hypertriglyceridemia (HTG). We performed the OFTT using 176 volunteers. The groups were divided according to fasting and postprandial triglyceride (TG) levels: 1) normal fat tolerance (NFT) group (TG at 0 h |
| doi_str_mv | 10.1507/endocrj.EJ22-0563 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2775951775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2837254796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-3f94985ea9b663504edc632fbd24b774027fa46eb2f67a9950d5de61ccea4c23</originalsourceid><addsrcrecordid>eNpdkU9v1DAQxS1ERZeWD8AFWeLCJa3jv_GxKqWAqvbSu-U4k64XJw62U7Tfnqx2yYHLzOX3nt7MQ-hjTa5qQdQ1jF10aXd195PSigjJ3qBNzXhTccHJW7Qhum6qRgt9jt7nvCOEMcHZO3TOpFKCNnKDwk3O0XlbfBxx7HGGNA_48elrFfwvwAkcTCUmPKVYwI-Y4QCvEDL-48sW-2GyPkGHe1twiQGSHR1gO3Z4u58gleRfwt5B8h0M3l6is96GDB9O-wI9f7t7vv1ePTzd_7i9eaicoLJUrNdcNwKsbqVkgnDonGS0bzvKW6U4oaq3XEJLe6ms1oJ0ogNZOweWO8ou0Jej7RL69wy5mMFnByHYEeKcDV2O16Je5oJ-_g_dxTmNSzhDG6ao4ErLhaqPlEsx5wS9mZIfbNqbmphDE-bUhDk0YQ5NLJpPJ-e5HaBbFf9evwD3R2CXi32BFbCpeBdgtVTEiMNYrVfCbW1aMPYXodGhFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2837254796</pqid></control><display><type>article</type><title>Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia</title><source>J-STAGE Free</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Zheng, Kunjie ; Li, Xiaolong ; Hou, Liping ; Gu, Wei ; Hou, Xiaoyu ; Wang, Chao ; Song, Guangyao</creator><creatorcontrib>Zheng, Kunjie ; Li, Xiaolong ; Hou, Liping ; Gu, Wei ; Hou, Xiaoyu ; Wang, Chao ; Song, Guangyao</creatorcontrib><description>The NOD-like receptor protein 3 (NLRP3) inflammasome plays a key role in lipid metabolism. We used an oral fat tolerance test (OFTT) to detect whether serum NLRP3 levels differed in people with different fat tolerances and evaluate whether NLRP3 was associated with impaired fat tolerance (IFT) and hypertriglyceridemia (HTG). We performed the OFTT using 176 volunteers. The groups were divided according to fasting and postprandial triglyceride (TG) levels: 1) normal fat tolerance (NFT) group (TG at 0 h <1.7 mmol/L and TG at any time point <2.5 mmol/L); 2) IFT group (TG at 0 h <1.7 mmol/L and TG at any time point >2.5 mmol/L); and 3) HTG group (TG at 0 h ≥1.7 mmol/L). With decreased lipid tolerance, the TG and NLRP3 levels increased gradually before a high-fat meal and at any time point after 0 h. NLRP3 levels reached a peak 2 h after meal consumption in all three groups. After adjustment for confounding indicators, logistic regression analysis revealed that fasting serum NLRP3 levels were positively associated with both IFT and HTG (for IFT, odds ratio [OR]: 1.079 [1.037–1.123], p < 0.001; for HTG, OR: 1.085 [1.049–1.123], p < 0.001). According to the receiver operating characteristic curve, fasting serum NLRP3 levels were an effective biomarker for IFT and HTG diagnosis. These results indicate that the fasting serum NLRP3 is an independent risk factor for IFT and HTG, and is a valuable indicator for the early diagnosis of IFT and HTG.</description><identifier>ISSN: 0918-8959</identifier><identifier>EISSN: 1348-4540</identifier><identifier>DOI: 10.1507/endocrj.EJ22-0563</identifier><identifier>PMID: 36775286</identifier><language>eng</language><publisher>Japan: The Japan Endocrine Society</publisher><subject>Blood Proteins ; Diagnosis ; Fasting ; Humans ; Hyperlipidemias ; Hypertriglyceridemia ; Hypertriglyceridemia - complications ; Impaired fat tolerance ; Inflammasomes ; Lipid metabolism ; NLR Family, Pyrin Domain-Containing 3 Protein ; NOD-like receptor protein 3 ; Oral fat tolerance test ; Risk factors ; Triglycerides</subject><ispartof>Endocrine Journal, 2023, Vol.70(5), pp.529-539</ispartof><rights>The Japan Endocrine Society</rights><rights>Copyright Japan Science and Technology Agency 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-3f94985ea9b663504edc632fbd24b774027fa46eb2f67a9950d5de61ccea4c23</citedby><cites>FETCH-LOGICAL-c526t-3f94985ea9b663504edc632fbd24b774027fa46eb2f67a9950d5de61ccea4c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,1877,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36775286$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Kunjie</creatorcontrib><creatorcontrib>Li, Xiaolong</creatorcontrib><creatorcontrib>Hou, Liping</creatorcontrib><creatorcontrib>Gu, Wei</creatorcontrib><creatorcontrib>Hou, Xiaoyu</creatorcontrib><creatorcontrib>Wang, Chao</creatorcontrib><creatorcontrib>Song, Guangyao</creatorcontrib><title>Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia</title><title>Endocrine Journal</title><addtitle>Endocr J</addtitle><description>The NOD-like receptor protein 3 (NLRP3) inflammasome plays a key role in lipid metabolism. We used an oral fat tolerance test (OFTT) to detect whether serum NLRP3 levels differed in people with different fat tolerances and evaluate whether NLRP3 was associated with impaired fat tolerance (IFT) and hypertriglyceridemia (HTG). We performed the OFTT using 176 volunteers. The groups were divided according to fasting and postprandial triglyceride (TG) levels: 1) normal fat tolerance (NFT) group (TG at 0 h <1.7 mmol/L and TG at any time point <2.5 mmol/L); 2) IFT group (TG at 0 h <1.7 mmol/L and TG at any time point >2.5 mmol/L); and 3) HTG group (TG at 0 h ≥1.7 mmol/L). With decreased lipid tolerance, the TG and NLRP3 levels increased gradually before a high-fat meal and at any time point after 0 h. NLRP3 levels reached a peak 2 h after meal consumption in all three groups. After adjustment for confounding indicators, logistic regression analysis revealed that fasting serum NLRP3 levels were positively associated with both IFT and HTG (for IFT, odds ratio [OR]: 1.079 [1.037–1.123], p < 0.001; for HTG, OR: 1.085 [1.049–1.123], p < 0.001). According to the receiver operating characteristic curve, fasting serum NLRP3 levels were an effective biomarker for IFT and HTG diagnosis. These results indicate that the fasting serum NLRP3 is an independent risk factor for IFT and HTG, and is a valuable indicator for the early diagnosis of IFT and HTG.</description><subject>Blood Proteins</subject><subject>Diagnosis</subject><subject>Fasting</subject><subject>Humans</subject><subject>Hyperlipidemias</subject><subject>Hypertriglyceridemia</subject><subject>Hypertriglyceridemia - complications</subject><subject>Impaired fat tolerance</subject><subject>Inflammasomes</subject><subject>Lipid metabolism</subject><subject>NLR Family, Pyrin Domain-Containing 3 Protein</subject><subject>NOD-like receptor protein 3</subject><subject>Oral fat tolerance test</subject><subject>Risk factors</subject><subject>Triglycerides</subject><issn>0918-8959</issn><issn>1348-4540</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9v1DAQxS1ERZeWD8AFWeLCJa3jv_GxKqWAqvbSu-U4k64XJw62U7Tfnqx2yYHLzOX3nt7MQ-hjTa5qQdQ1jF10aXd195PSigjJ3qBNzXhTccHJW7Qhum6qRgt9jt7nvCOEMcHZO3TOpFKCNnKDwk3O0XlbfBxx7HGGNA_48elrFfwvwAkcTCUmPKVYwI-Y4QCvEDL-48sW-2GyPkGHe1twiQGSHR1gO3Z4u58gleRfwt5B8h0M3l6is96GDB9O-wI9f7t7vv1ePTzd_7i9eaicoLJUrNdcNwKsbqVkgnDonGS0bzvKW6U4oaq3XEJLe6ms1oJ0ogNZOweWO8ou0Jej7RL69wy5mMFnByHYEeKcDV2O16Je5oJ-_g_dxTmNSzhDG6ao4ErLhaqPlEsx5wS9mZIfbNqbmphDE-bUhDk0YQ5NLJpPJ-e5HaBbFf9evwD3R2CXi32BFbCpeBdgtVTEiMNYrVfCbW1aMPYXodGhFg</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Zheng, Kunjie</creator><creator>Li, Xiaolong</creator><creator>Hou, Liping</creator><creator>Gu, Wei</creator><creator>Hou, Xiaoyu</creator><creator>Wang, Chao</creator><creator>Song, Guangyao</creator><general>The Japan Endocrine Society</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20230101</creationdate><title>Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia</title><author>Zheng, Kunjie ; Li, Xiaolong ; Hou, Liping ; Gu, Wei ; Hou, Xiaoyu ; Wang, Chao ; Song, Guangyao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-3f94985ea9b663504edc632fbd24b774027fa46eb2f67a9950d5de61ccea4c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Blood Proteins</topic><topic>Diagnosis</topic><topic>Fasting</topic><topic>Humans</topic><topic>Hyperlipidemias</topic><topic>Hypertriglyceridemia</topic><topic>Hypertriglyceridemia - complications</topic><topic>Impaired fat tolerance</topic><topic>Inflammasomes</topic><topic>Lipid metabolism</topic><topic>NLR Family, Pyrin Domain-Containing 3 Protein</topic><topic>NOD-like receptor protein 3</topic><topic>Oral fat tolerance test</topic><topic>Risk factors</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Kunjie</creatorcontrib><creatorcontrib>Li, Xiaolong</creatorcontrib><creatorcontrib>Hou, Liping</creatorcontrib><creatorcontrib>Gu, Wei</creatorcontrib><creatorcontrib>Hou, Xiaoyu</creatorcontrib><creatorcontrib>Wang, Chao</creatorcontrib><creatorcontrib>Song, Guangyao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Kunjie</au><au>Li, Xiaolong</au><au>Hou, Liping</au><au>Gu, Wei</au><au>Hou, Xiaoyu</au><au>Wang, Chao</au><au>Song, Guangyao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia</atitle><jtitle>Endocrine Journal</jtitle><addtitle>Endocr J</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>70</volume><issue>5</issue><spage>529</spage><epage>539</epage><pages>529-539</pages><artnum>EJ22-0563</artnum><issn>0918-8959</issn><eissn>1348-4540</eissn><abstract>The NOD-like receptor protein 3 (NLRP3) inflammasome plays a key role in lipid metabolism. We used an oral fat tolerance test (OFTT) to detect whether serum NLRP3 levels differed in people with different fat tolerances and evaluate whether NLRP3 was associated with impaired fat tolerance (IFT) and hypertriglyceridemia (HTG). We performed the OFTT using 176 volunteers. The groups were divided according to fasting and postprandial triglyceride (TG) levels: 1) normal fat tolerance (NFT) group (TG at 0 h <1.7 mmol/L and TG at any time point <2.5 mmol/L); 2) IFT group (TG at 0 h <1.7 mmol/L and TG at any time point >2.5 mmol/L); and 3) HTG group (TG at 0 h ≥1.7 mmol/L). With decreased lipid tolerance, the TG and NLRP3 levels increased gradually before a high-fat meal and at any time point after 0 h. NLRP3 levels reached a peak 2 h after meal consumption in all three groups. After adjustment for confounding indicators, logistic regression analysis revealed that fasting serum NLRP3 levels were positively associated with both IFT and HTG (for IFT, odds ratio [OR]: 1.079 [1.037–1.123], p < 0.001; for HTG, OR: 1.085 [1.049–1.123], p < 0.001). According to the receiver operating characteristic curve, fasting serum NLRP3 levels were an effective biomarker for IFT and HTG diagnosis. These results indicate that the fasting serum NLRP3 is an independent risk factor for IFT and HTG, and is a valuable indicator for the early diagnosis of IFT and HTG.</abstract><cop>Japan</cop><pub>The Japan Endocrine Society</pub><pmid>36775286</pmid><doi>10.1507/endocrj.EJ22-0563</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-8959 |
| ispartof | Endocrine Journal, 2023, Vol.70(5), pp.529-539 |
| issn | 0918-8959 1348-4540 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2775951775 |
| source | J-STAGE Free; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Blood Proteins Diagnosis Fasting Humans Hyperlipidemias Hypertriglyceridemia Hypertriglyceridemia - complications Impaired fat tolerance Inflammasomes Lipid metabolism NLR Family, Pyrin Domain-Containing 3 Protein NOD-like receptor protein 3 Oral fat tolerance test Risk factors Triglycerides |
| title | Association of serum NOD-like receptor protein 3 levels with impaired fat tolerance and hypertriglyceridemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T20%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20serum%20NOD-like%20receptor%20protein%203%20levels%20with%20impaired%20fat%20tolerance%20and%20hypertriglyceridemia&rft.jtitle=Endocrine%20Journal&rft.au=Zheng,%20Kunjie&rft.date=2023-01-01&rft.volume=70&rft.issue=5&rft.spage=529&rft.epage=539&rft.pages=529-539&rft.artnum=EJ22-0563&rft.issn=0918-8959&rft.eissn=1348-4540&rft_id=info:doi/10.1507/endocrj.EJ22-0563&rft_dat=%3Cproquest_cross%3E2837254796%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2837254796&rft_id=info:pmid/36775286&rfr_iscdi=true |